Search
ProQR Therapeutics NV
PRQRAdd to Watchlist
1.720USD
-0.060-3.37%
Close 07-31 16:00（ET）Quotes delayed by 15 min
228.74MMarket Cap
LossP/E TTM
More Details of ProQR Therapeutics NV Company
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV Info
Ticker SymbolPRQR
Company nameProQR Therapeutics NV
IPO dateSep 18, 2014
CEOde Boer (Daniel Anton)
Number of employees166
Security typeOrdinary Share
Fiscal year-endSep 18
AddressZernikedreef 9
CityLEIDEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code2333 CK
Phone31881667000
Websitehttps://www.proqr.com/
Ticker SymbolPRQR
IPO dateSep 18, 2014
CEOde Boer (Daniel Anton)
Company Executives of ProQR Therapeutics NV
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
300.00K
+50.00%
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
300.00K
+50.00%
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
FAQs
Who are the top five shareholders of ProQR Therapeutics NV?
The top five shareholders of ProQR Therapeutics NV are: Mr. Gerard Platenburg, Ph.D.
How many institutions hold shares of ProQR Therapeutics NV (PRQR)?
As of 2026Q1, 122 institutions hold shares of ProQR Therapeutics NV, with a combined market value of approximately 38.34M, accounting for 36.39% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5670621.00.